The Antisense & RNAi Therapeutics by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Antisense & RNAi Therapeutics Market:
https://www.thebusinessresearchcompany.com/report/antisense-and-rnai-therapeutics-global-market-report
According to The Business Research Company’s Antisense & RNAi Therapeutics, The antisense & rnai therapeutics market size has grown rapidly in recent years. It will grow from $1.59 billion in 2023 to $1.77 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to rise in funding, advancement in technologies, and rise in healthcare expenditure, rapid growth in elderly population and economic growth in emerging markets.
The antisense & rnai therapeutics market size is expected to see rapid growth in the next few years. It will grow to $2.81 billion in 2028 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increase in healthcare access, rising prevalence of caner and increasing demand for antisense and rnai therapeutics due to covid-19. Major trends in the forecast period include focus efforts towards the research and development of rna therapeutics for orphan diseases, use of nanoparticles, develop new and improved antisense and rnai therapeutics, and collaborate with other companies for product innovation and to drive revenues.
The rising prevalence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is projected to contribute to the demand for the antisense & RNAi therapeutics market. Gene suppression approaches including RNA interference and antisense oligonucleotides are used for the treatment of various neurodegenerative conditions by repairing mutant genes. According to the National Institute of Environmental Health Sciences, Alzheimer’s disease and Parkinson’s disease are the most common neurodegenerative diseases affecting millions of people globally. In the USA, 6.2 million people may have Alzheimer’s disease in the USA . As per January 2023 data approximately 500,000 people in the USA are diagnosed with Parkinson’s disease. Hence, the growing prevalence of several neurodegenerative diseases and infectious diseases is expected to drive the growth of the antisense & RNAi therapeutics market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=3389&type=smp
The antisense & rnai therapeutics market covered in this report is segmented –
1) By Technology: RNA Interference, Antisense RNA
2) By Route of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods
3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications
Major companies operating in the antisense & RNAi therapeutics market are undertaking strategic initiatives, such as collaborations and partnerships to sustain in the increasingly competitive market. Strategic collaboration is a business strategy that involves two or more companies working together to achieve a common goal or objective. For instance, in January 2023, Orbit Discovery Limited, a US-based company offering services for the discovery of peptides has partnered with SanegeneBio Inc. a UK-based company involved in the developing novel RNAi-based medicines for the identification of tissue-specific delivery of RNA therapeutics for efficient gene knockdown, aiming to develop a portfolio of advanced RNAi therapeutics. The collaboration encompasses hit identification and cell-based internalization studies, with Sanegene having the option to further develop the hits derived from the screening activities, leveraging Orbit’s proprietary technology for rapid peptide lead discovery. Orbit Discovery’s unique peptide display engine enables the screening of large peptide libraries, offering faster discovery times for relevant peptide leads based on affinity and functional screens.
The antisense & rnai therapeutics market report table of contents includes:
1. Executive Summary
2.Antisense & RNAi Therapeutics Market Characteristics
3.Antisense & RNAi Therapeutics Market Trends And Strategies
4. Antisense & RNAi Therapeutics Market analysis
5.Antisense & RNAi Therapeutics Market Size And Growth
6. Antisense & RNAi TherapeuticsSegmentation
7.Antisense & RNAi Therapeutics Regional And Country Analysis
.
.
.
27.Antisense & RNAi Therapeutics Competitive Landscape And Company Profiles
28.Antisense & RNAi Therapeutics Key Mergers And Acquisitions
29.Antisense & RNAi Therapeutics Future Outlook and Potential Analysis
TOP MAJOR PLAYERS:
- Biogen Inc.
- Ionis Pharmaceuticals Inc.
- Alnylam Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Inc.
- Moderna Inc.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
